Profile data is unavailable for this security.
About the company
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.
- Revenue in USD (TTM)644.40m
- Net income in USD137.55m
- Incorporated2004
- Employees1.76k
- LocationAmphastar Pharmaceuticals Inc11570 6th StRANCHO CUCAMONGA 91730United StatesUSA
- Phone+1 (909) 980-9484
- Fax+1 (302) 655-5049
- Websitehttps://amphastar.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Recursion Pharmaceuticals Inc | 44.58m | -328.07m | 1.86bn | 500.00 | -- | 3.95 | -- | 41.67 | -1.57 | -1.57 | 0.2145 | 1.98 | 0.0658 | -- | 15.25 | 89,150.00 | -48.42 | -- | -56.49 | -- | 4.46 | -- | -735.99 | -- | -- | -- | 0.0025 | -- | 11.88 | -- | -36.99 | -- | -- | -- |
Amneal Pharmaceuticals Inc | 2.39bn | -83.99m | 1.87bn | 7.70k | -- | 140.29 | 10.33 | 0.7799 | -0.3116 | -0.3116 | 13.46 | 0.0431 | 0.6583 | 2.83 | 3.53 | 310,858.10 | -1.34 | -4.80 | -1.70 | -5.93 | 34.28 | 34.76 | -2.04 | -9.00 | 0.9408 | 1.14 | 0.9778 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
Tilray Brands Inc | 743.25m | -351.95m | 1.91bn | 1.60k | -- | 0.5692 | -- | 2.57 | -0.4979 | -0.4979 | 1.04 | 4.34 | 0.1731 | 2.39 | 8.85 | 464,530.00 | -7.61 | -- | -8.38 | -- | 28.01 | -- | -43.98 | -- | 1.18 | 0.2252 | 0.1216 | -- | -0.1986 | -- | -204.67 | -- | -- | -- |
Rocket Pharmaceuticals Inc | 0.00 | -245.60m | 1.95bn | 268.00 | -- | 3.94 | -- | -- | -2.94 | -2.94 | 0.00 | 5.46 | 0.00 | -- | -- | 0.00 | -43.93 | -35.26 | -47.67 | -37.49 | -- | -- | -- | -- | -- | -- | 0.0412 | -- | -- | -- | -10.70 | -- | 62.52 | -- |
Sana Biotechnology Inc | 0.00 | -283.26m | 1.97bn | 328.00 | -- | 6.19 | -- | -- | -1.46 | -1.46 | 0.00 | 1.45 | 0.00 | -- | -- | 0.00 | -40.81 | -38.99 | -46.74 | -42.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.11 | -- | 112.71 | -- |
Amphastar Pharmaceuticals Inc | 644.40m | 137.55m | 2.02bn | 1.76k | 15.94 | 3.10 | 11.35 | 3.13 | 2.59 | 2.59 | 12.16 | 13.30 | 0.5716 | 2.78 | 6.33 | 365,925.60 | 12.38 | 9.42 | 14.42 | 11.56 | 54.91 | 47.83 | 21.65 | 15.23 | 1.70 | 10.68 | 0.4799 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
Keros Therapeutics Inc | 151.00k | -152.99m | 2.03bn | 136.00 | -- | 5.40 | -- | 13,469.29 | -5.19 | -5.19 | 0.0051 | 10.43 | 0.0005 | -- | 2.11 | 1,110.29 | -45.21 | -35.95 | -48.12 | -38.07 | -- | -- | -101,319.20 | -1,237.26 | -- | -- | 0.00 | -- | -- | -56.77 | -46.15 | -- | 62.57 | -- |
Intellia Therapeutics Inc | 36.28m | -481.19m | 2.06bn | 526.00 | -- | 1.90 | -- | 56.70 | -5.42 | -5.42 | 0.4106 | 11.29 | 0.0257 | -- | 1.80 | 68,963.88 | -34.11 | -31.34 | -37.31 | -34.53 | -- | -- | -1,326.51 | -654.71 | -- | -- | 0.00 | -- | -30.40 | 3.57 | -1.48 | -- | 17.08 | -- |
Maravai Lifesciences Holdings Inc | 288.95m | -119.03m | 2.06bn | 650.00 | -- | 4.94 | -- | 7.13 | -0.901 | -0.901 | 2.19 | 1.66 | 0.1533 | 3.15 | 2.99 | 444,530.80 | -7.34 | 12.67 | -9.75 | 15.46 | 48.52 | 74.79 | -47.89 | 37.32 | 7.41 | -0.3566 | 0.4134 | 0.00 | -67.28 | 18.47 | -154.05 | -- | 78.56 | -- |
Kymera Therapeutics Inc | 78.59m | -146.96m | 2.06bn | 187.00 | -- | 4.73 | -- | 26.25 | -2.52 | -2.52 | 1.35 | 7.11 | 0.1333 | -- | 7.38 | 420,278.10 | -24.93 | -23.03 | -28.76 | -27.64 | -- | -- | -186.99 | -207.82 | -- | -- | 0.0065 | -- | 67.84 | -- | 5.07 | -- | 91.01 | -- |
Deciphera Pharmaceuticals Inc | 163.36m | -194.94m | 2.08bn | 355.00 | -- | 5.80 | -- | 12.72 | -2.29 | -2.29 | 1.92 | 4.36 | 0.3522 | 0.1787 | 6.01 | 460,157.80 | -42.03 | -44.54 | -52.63 | -52.24 | 97.72 | -- | -119.34 | -245.88 | 3.59 | -- | 0.00 | -- | 21.87 | -- | -8.95 | -- | -7.11 | -- |
TG Therapeutics Inc | 233.66m | 12.67m | 2.11bn | 264.00 | 967.42 | 12.89 | 163.73 | 9.03 | 0.0141 | 0.0141 | 1.61 | 1.06 | 0.8933 | -- | 9.15 | 885,087.10 | 4.84 | -62.87 | 6.09 | -80.06 | 93.95 | -- | 5.42 | -405.03 | 5.18 | 1.64 | 0.3842 | -- | 8,290.02 | 333.86 | 106.39 | -- | -- | -- |
Vera Therapeutics Inc | 0.00 | -95.99m | 2.15bn | 51.00 | -- | 17.27 | -- | -- | -2.28 | -2.28 | 0.00 | 2.29 | 0.00 | -- | -- | 0.00 | -62.54 | -- | -74.10 | -- | -- | -- | -- | -- | -- | -- | 0.3291 | -- | -- | -- | -7.79 | -- | -- | -- |
Arvinas Inc | 78.50m | -367.30m | 2.17bn | 445.00 | -- | 3.27 | -- | 27.65 | -6.62 | -6.62 | 1.45 | 9.71 | 0.061 | -- | 157.00 | 176,404.50 | -28.35 | -22.01 | -36.10 | -26.47 | -- | -- | -464.71 | -316.55 | -- | -- | 0.0012 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Dec 2023 | 5.58m | 11.61% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 2.70m | 5.62% |
Federated Global Investment Management Corp.as of 29 Feb 2024 | 2.17m | 4.50% |
Neuberger Berman Investment Advisers LLCas of 31 Dec 2023 | 1.69m | 3.52% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 1.47m | 3.06% |
Dimensional Fund Advisors LPas of 31 Dec 2023 | 1.34m | 2.78% |
Fuller & Thaler Asset Management, Inc.as of 31 Dec 2023 | 1.27m | 2.65% |
Geode Capital Management LLCas of 31 Dec 2023 | 846.65k | 1.76% |
TD Asset Management, Inc.as of 31 Dec 2023 | 793.56k | 1.65% |
Renaissance Technologies LLCas of 31 Dec 2023 | 641.90k | 1.34% |